This activity has expired. Credit is no longer available.
This activity is supported by educational grants provided by Amgen, AstraZeneca, Celgene Corporation, Incyte Corporation, Merck Sharp & Dohme Corp., Takeda Oncology, Pharmacyclics LLC, an AbbVie Company, and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.
Emerging Therapies for Hodgkin Lymphoma
Patrick J. Kiel, PharmD, BCPS, BCOP
IU Simon Cancer Center
In this lecture, learn about the principles of treatment for relapsed/refractory classical Hodgkin lymphoma, including therapeutic targets and mechanisms of action of newly approved agents in order to educate and manage patients effectively. Hear from an expert in the field on best practices for treating immune-related adverse events such as pneumonitis, hyperthyroidism, and colitis.
|
|
These activities, certified for CME/CE/CPE credit, are jointly provided by
  |